Trials / Completed
CompletedNCT00047658
A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Biology, and Clinical Effects of Interferon Gamma-1b Administered Subcutaneously to Patients With IPF Followed by an Open-Label Extension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- InterMune · Industry
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
Study GIPF-002 is a phase 2 study designed to characterize the biologic and clinical effects of IFN-g 1b. The objective of the Study is to characterize the biologic and clinical effects of IFN-g 1b administered to patients with idiopathic pulmonary fibrosis (IPF). The Study will be conducted at multiple sites and enroll 30 patients with IPF who have failed treatment with corticosteroids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon-gamma 1b | 200 mcg, SQ, 3x per week |
Timeline
- Start date
- 2001-11-01
- Completion
- 2003-05-01
- First posted
- 2002-10-11
- Last updated
- 2007-11-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00047658. Inclusion in this directory is not an endorsement.